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Mitochondrial diseases due to mutations in the mitochondrial (mt) DNA are heterogeneous in clinical 
manifestations but usually include OXPHOS dysfunction. Mechanisms by which OXPHOS dysfunction 
contributes to the disease phenotype invoke, apart from cell energy deficit, maladaptive responses to 
mitochondria-to-nucleus retrograde signaling. Here we used five different cybrid models of mtDNA 
diseases to demonstrate that the expression of the nuclear-encoded mt-tRNA modification enzymes 
TRMU, GTPBP3 and MTO1 varies in response to specific pathological mtDNA mutations, thus altering 
the modification status of mt-tRNAs. Importantly, we demonstrated that the expression of TRMU, 
GTPBP3 and MTO1 is regulated by different miRNAs, which are induced by retrograde signals like ROS 
and Ca2+ via different pathways. Our data suggest that the up- or down-regulation of the mt-tRNA 
modification enzymes is part of a cellular response to cope with a stoichiometric imbalance between 
mtDNA- and nuclear-encoded OXPHOS subunits. However, this miRNA-mediated response fails to 
provide full protection from the OXPHOS dysfunction; rather, it appears to aggravate the phenotype 
since transfection of the mutant cybrids with miRNA antagonists improves the energetic state of the 
cells, which opens up options for new therapeutic approaches.
Mitochondrial diseases caused by impairment of mitochondrial translation are highly heterogeneous in etiology 
and clinical manifestations but usually include oxidative phosphorylation (OXPHOS) dysfunction1. Mechanisms 
by which OXPHOS dysfunction contributes to the disease phenotype are not well-understood but they likely 
involve retrograde signaling from mitochondria to nucleus triggered by changes in metabolite homeostasis, such 
as ROS, Ca2+, ADP/ATP and NAD/NADH2–5. Understanding how these changes lead to maladaptive responses 
upon OXPHOS dysfunction may help to find new therapeutic strategies.
The human mitochondrial genome (mtDNA) encodes thirteen structural subunits of the OXPHOS complexes 
I, III, IV and V, and the 22 tRNAs and 2 rRNAs used for intra-mitochondrial protein synthesis. More than 50% 
of the pathogenic mtDNA mutations occur in tRNA genes6. Some of them affect mt-tRNALys and mt-tRNALeu 
causing MERRF and MELAS, respectively7. These mutations prevent the modification of the anticodon wobble 
uridine (U34), which disturbs the function of the mutant tRNAs in translation8, 9. Modifications of U34 in a 
mt-tRNA set depend on the nuclear-encoded proteins GTPBP3 and MTO1 (which jointly introduce the tau-
rinomethyl group at position 5 of the pyrimidine ring in mt-tRNALys, mt-tRNALeu, mt-tRNAGln, mt-tRNAGlu, and 
mt-tRNATrp), and TRMU (which thiolates U34 at position 2 in mt-tRNALys, mt-tRNAGln, and mt-tRNAGlu)10, 11. 
Mutations directly affecting GTPBP3 and MTO1 cause infantile hypertrophic cardiomyopathy12–14, whereas 
TRMU mutations cause infantile hepatopathy, which is fatal in some instances and reversible in others for 
unknown reasons15–17.
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Cells carrying MELAS mutations exhibit mitochondrial translation defects, oxidative stress, and diminished 
respiratory enzyme activity and oxygen consumption18–21. In addition to OXPHOS dysfunction resulting from 
altered mitochondrial translation, other mechanisms contribute to the MELAS phenotype. Thus, the MELAS 
mutation A3243G induces, in a cell model, a retrograde signaling pathway involving ROS, kinase JNK, reti-
noid X receptor α and transcriptional coactivator PGC1α3. This pathway leads to a decrease in the mRNA lev-
els of nuclear-encoded OXPHOS subunits, thereby aggravating the OXPHOS dysfunction. Moreover, we have 
recently shown that the high levels of ROS caused by the MELAS mutation A3243G induce, via an NFkB path-
way, the expression of microRNA 9/9* (miR-9/9*), which reduces the steady-state levels of TRMU, GTPBP3 
and MTO1 because of their mRNAs are direct targets of miR-9 (TRMU and GTPBP3) and miR-9* (MTO1)4. 
Down-regulation of these enzymes affects the U34 modification of non-mutant mt-tRNAs and contributes to 
the MELAS phenotype in a cell model. These data provided the first evidence that the modification status of 
mt-tRNAs is dynamic, as previously observed in cytosolic tRNAs22, and that cells respond to oxidative stress by 
reducing the expression of mt-tRNA modification enzymes through the action of a miRNA.
In this paper, we investigate whether deregulation of TRMU, GTPBP3, and MTO1 also participates in the cell 
response to the stress caused by pathogenic mutations in other mtDNA genes, including non-substrate mt-tRNA 
and protein-encoding genes. Transmitochondrial cytoplasmic hybrids (cybrids) are appropriate cell models to 
compare in the same nuclear background the effects of different homoplasmic mtDNA mutations. Thus, we com-
pared the expression of GTPBP3, MTO1 and TRMU genes among cybrid cells carrying mutations in mt-tRNALeu 
(m.3243 A > G, MELAS), mt-tRNALys (m.8344 A > G, MERRF), mt-tRNATrp (m.5514 A > G, m.Trp) or mt-tRNAVal 
(m.1643A > G, m.Val) genes, all of them associated with severe encephalomyopathic phenotypes (Table 1)23, 24. 
In addition, we included in the study the m.14487 T > C mutation in the ND6 gene (m.ND6), which is causative 
of a progressive generalized dystonia and bilateral striatal necrosis (Table 1)25, as an example of mtDNA mutation 
affecting a protein-encoding gene. We found that variations in the steady-state levels of U34 modifying proteins 
are noticeable in all the selected cellular models of mt-DNA diseases, which suggests that regulation of these 
enzymes is part of the adaptive/maladaptive response to OXPHOS dysfunction. mtDNA mutations lead to up- or 
down-regulation of specific U34 modification enzymes depending partially on the cellular miRNA expression 
pattern, which is associated with the levels of retrograde signals. Our work supports the view that stress-induced 
reprogramming of mt-tRNA modifications occurs under certain pathological conditions and that miRNAs are key 
regulators of the mt-tRNA modification enzymes and, consequently, of the mt-tRNA functions.
Results
The selected disease cell models exhibit different profiles of proteotoxic stress, OXPHOS dys-
function, and retrograde signals. Mutations in mtDNA genes encoding mt-tRNA or OXPHOS subunits 
may lead to disruption of stoichiometric balance between components of OXPHOS complexes, thus unleashing 
proteotoxic stress5, 26, 27. Common markers of this stress are mitoproteases LONP1, AFG3L2 and CLPP, which, 
in addition to their roles in protein quality control, are involved in various biological processes such as mtDNA 
maintenance and mitoribosome assembly27. LONP1 is the major matrix protease responsible for degradation 
of unfolded or misfolded proteins before their aggregation28, and also controls mtDNA maintenance and gene 
expression27; AFG3L2 is integrated into the inner mitochondrial membrane and appears to be important for dest-
abilization of OXPHOS complexes containing incorrect proteins, removal of orphaned OXPHOS proteins26, 29, 30, 
ribosome assembly, and synthesis of mtDNA-encoded OXPHOS subunits31, 32; finally, CLPP has been recently 
shown to play an essential role in determining the rate of mitochondrial protein synthesis; loss of CLPP leads to 
Cybrid cell 
name MELAS MERRF m.Val m.Trp m.ND6
tRNA/
protein and 
mutation
tRNA Leu m.3243 A > G (MELAS) tRNA Lys m. 8344 A > G (MERRF) tRNA Val m. 1643A > G tRNA 
Trp m. 
5514 A > G ND6 m.14487 T > C
Organ Clinical features
Brain
Stroke-like episodes, typically before 
age 40 years Encephalopathy with 
seizures and/or dementia Normal early 
psychomotor development Recurrent 
headache
Myoclonus Generalized epilepsy Ataxia 
Dementia Pyramidal signs
Normal early psychomotor 
development Epilepsy Brain atrophy 
Dyskinetic movement Dystonic 
tetraplegia Loss of oral communication
Reduced 
spontaneous 
movements
Progressive 
generalized 
dystonia and 
bilateral striatal 
necrosis
Nerve Recurrent vomiting Peripheral neuropathy Peripheral neuropathy
Global delay 
in myelination 
Recurrent vomiting
Muscle
Mitochondrial myopathy, evidenced by 
lactic acidosis and/or ragged red fibers 
(RRF) on muscle biopsy
Myopathy Ragged-red fibers (RRF) in 
the muscle biopsy Ophthalmoparesis Muscle atrophy Lactic acidosis
Muscle atrophy 
Hypotonia Lactic 
acidosis.
Heart Cardiomyopathy
Eyes Optic atrophy Pigmentary retinopathy
Ears Sensorineural hearing loss
Systemic Exercise intolerance Short stature Multiple lipomas
Low weight and 
height
Reference 23 23 24 24 25
Table 1. Brief summary of clinical symptoms associated with each mutation.
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a moderate defect in mitochondrial translation that may have compensatory effects in certain pathogenic con-
texts33, 34. As shown in Fig. 1A and B, the levels of LONP1 were increased in all mutant cybrid lines with exception 
of m.Trp cells, expression of AFG3L2 was induced in all disease cell models except MELAS, and the levels of 
CLPP were increased in MELAS, m.Val and m.ND6 cells, whereas they were reduced in MERRF and m.Trp cells. 
Therefore, there exists a disease-specific expression pattern of these mitoproteases in the cybrid lines. We con-
clude that each mtDNA mutation triggers a specific protease response as a consequence of a different proteotoxic 
scenario.
The determination of the steady-state levels of OXPHOS complexes in mutant and wild type (WT) cybrid cells 
by blue native polyacrylamide gel electrophoresis (BN-PAGE) showed that the severity of OXPHOS defects varies 
with the mutation, being more drastic in MELAS and MERRF cells, with affectation of complexes I, III, IV and V. 
Figure 1. Altered mitochondrial features in cybrid cells carrying MELAS, MERRF, m.5514 A > G (mt-
tRNATrp), m.1643A > G (mt-tRNAVal), and m.14487 T > C (ND6) mutations. (A) Representative western blot 
of LONP1, AFG3L2 and CLPP peptidases in mutant and wild type (WT) cybrid cells. The membrane was also 
probed with porin as a loading control. Full-length western blots and lower-exposure blots of porin are included 
in supplementary information. (B) Densitometric analysis of LONP1, AFG3L2 and CLPP normalized to porin 
and represented as fold change relative to WT (top). Quantitative data are from at least three independent 
experiments. Results from this analysis are also shown as a heatmap (bottom). The color and the corresponding 
value in log2 scale are depicted on the left. (C) Representative Blue Native-PAGE of OXPHOS complexes 
in mutant and WT cybrid cells. Full-length blots and lower-exposure blots for those with high contrast are 
included in supplementary information. (D) Densitometric analysis of OXPHOS complexes normalized to 
complex-II (loading control) and represented as fold change relative to WT. (E) Cellular ATP determination in 
mutant and WT cybrid cells. (F and G) Determination of Ca2+ (F) and ROS (G) by flow cytometry in mutant 
and WT cybrid cells with Fluo-3 and MitoSOX Red, respectively. All data are the mean ± SEM of at least 
three different experiments. Differences from WT values were found to be statistically significant at *p < 0.05, 
**p < 0.01 and ***p < 0.001.
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Conversely, we could not detect any reduction in the levels of OXPHOS complexes in m.ND6 cells (Fig. 1C and 
D), despite activity of complex I was found to be decreased in this cybrid line25. This finding suggests that complex 
I may be misfolded and/or misassembled in m.ND6 cells.
It is worthy to mention that the decrease in the steady-state levels of OXPHOS complexes containing 
mtDNA-encoded subunits (CI, CIII, CIV, and CV) observed in MELAS and MERRF cybrids is not due to a 
lower content of mtDNA (in relation to nDNA) since no differences in the mtDNA copy number were observed 
between the mutant and WT cybrid lines (Fig. S1).
The cellular consequences of the OXPHOS dysfunction include changes in a variety of metabolites such as ATP, 
ROS and Ca2+, which act as signals in retrograde mitochondria-nucleus communication. We found 60% and 50% 
reduction of ATP levels in MELAS and MERRF cybrid cells, respectively, in comparison to WT cybrid cells, whereas 
the reduction was more moderate in m.Val (~30%), m.Trp (~20%) and m.ND6 cells (~20%) (Fig. 1E). Determination 
of the intracellular calcium (Ca2+) and superoxide anion (O2·−) levels by flow cytometry showed elevated levels in all 
the mutant cybrid cells, as compared to WT cells, although these traits were again more prominent in MELAS and 
MERRF cells (Fig. 1F and G). Notably, the m.ND6 cells exhibited the lowest increase in the intracellular Ca2+ levels 
(Fig. 1F). Altogether these results suggest that the intensity of changes in the retrograde signals ATP, Ca2+ and ROS is 
not equal for all the mutant cybrids, which is likely a consequence of the particular effects of each mtDNA mutation.
Altered levels of U34 modification enzymes is a common trait in all the selected cybrid lines. The 
mRNA and protein expression levels of the GTPBP3, MTO1 and TRMU genes were evaluated in the cybrid cells by 
qRT-PCR and Western Blot (Fig. 2). A reduction in the mRNA and protein levels of GTPBP3 and MTO1 was found in 
all the disease cell models except m.ND6 (Fig. 2A–E). The expression of TRMU was decreased in MELAS and MERRF 
cybrids but increased in m.Trp and m.Val cells (Fig. 2C–E). A tendency for increased levels of the three U34 modifi-
cation enzymes was observed in m.ND6 cells (Fig. 2E), despite no increase was detected at mRNA levels (Fig. 2A–C).
To explore the direct effects of the deregulation of the enzymes, we analyzed the thiolation status of mt-tRNALys 
in MELAS and m.ND6 cybrid lines, in which protein TRMU was found to be down- and up-regulated, respec-
tively (Fig. 2E). To this end, we used APM-Northern blotting, which relies on the retardation of thiolated tRNA 
Figure 2. Specific expression pattern of U34 modifying enzymes in the different cybrid cells. (A–C) qRT-PCR 
analysis of GTPBP3 (A), MTO1 (B) and TRMU (C) mRNA expression in mutant and WT cybrid cells.  
(D) Western blot analysis of GTPBP3, MTO1 and TRMU in mutant and WT cybrid cells. The membrane 
was also probed with porin as a loading control. Full-length western blots are included in supplementary 
information. (E) Densitometric analysis of GTPBP3, MTO1 and TRMU normalized to porin and represented 
as fold change relative to WT (top). Results from this analysis are also shown as a heatmap (bottom). The 
color and the corresponding value in log2 scale are depicted on the left. All data are the mean ± SEM of at least 
three different experiments. Differences from WT values were found to be statistically significant at *p < 0.05, 
**p < 0.01 and ***p < 0.001. AU: arbitrary units.
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molecules because of the affinity of the thio group for the p-(N-acrylamino)-phenylmercuric chloride (APM) 
compound in the gel35. As shown in Fig. 3, the non-thiolated mt-tRNALys fraction was increased in MELAS 
(where TRMU is down-expressed) and reduced in m.ND6 (where TRMU is up-expressed). Our data also indicate 
that mt-tRNALys is partially 2-thiolated even in WT cells, a condition that has been observed in other scenarios36, 
and support the idea that the non-thiolated/thiolated ratio of mt-tRNALys molecules depends on the expres-
sion level of TRMU in each cybrid line. Although we observed a direct correlation between the levels of TRMU 
and 2-thiolation, there is no perfect match between fold-changes for both parameters. This could be due to the 
semi-quantitative nature of the APM-Northern and Western blotting analysis, to a higher stability of thiolated 
mt-tRNA molecules, which could affect the non-thiolated/thiolated ratio, and/or to features of the TRMU protein 
that remain to be determined.
The cybrid lines exhibit a differential expression of ROS-sensitive miRNAs that target the 
U34 modification enzymes. We previously demonstrated that the ROS-sensitive microRNA-9/9* 
down-regulates the expression of GTPBP3, MTO1 and TRMU in MELAS cells4. To select additional, putative 
ROS-sensitive microRNAs that may regulate the expression of these proteins in the different cybrid models, we 
created a list of microRNAs predicted to bind to the 3′UTR region of the GTPBP3, MTO1 and TRMU mRNAs 
according to three databases (miRanda, miRWalk and Targetscan). From this list, we only kept microRNAs asso-
ciated with an oxidative stress scenario4, which then were classified by the number of targeted enzymes (in order 
to identify putative miRNAs that can control simultaneously several U34 modification enzymes) and, subse-
quently, by the number of databases showing the microRNA-target interaction (Table S1). We selected miR-9/9*, 
miR-335/335* and miR-338-3p for experimental validation as they presented the highest total scores.
Expression of miR-9/9* was found to be induced in MELAS and MERRF cells (Fig. 4A and D), as expected4. 
However, no changes in the miRNA-9/9* levels were observed in m.Trp and m.Val cells, whereas a noticeable 
decrease in the expression of this miRNA was found in m.ND6 cells (Fig. 4A and D). miR-338-3p followed the 
expression pattern of miR-9/9* (compare Fig. 4A and B, or see Fig. 4D), although its absolute abundance was 
lower in all cybrid lines, as inferred from qRT-PCR data (see Materials and Methods).
Since the expression of miR-9/9* and miR-338-3p is not affected in m.Trp and m.Val, other miRNA(s) could 
be responsible for the decrease of the GTPBP3 and MTO1 levels observed in these cells (Fig. 2E). We thought 
that miR-335/335* could be a good candidate given that the 3′ UTR region of GTPBP3 and MTO1, but not that 
of TRMU (whose expression is increased in m.Trp and m.Val), have predicted binding sites for this miRNA 
(Table S1). Indeed, we found that the expression of miR-335/335* was induced in m.Trp and m.Val, remained 
unaltered in MELAS and MERRF, and was drastically reduced in m.ND6 (Fig. 4C and D).
Next we evaluated the regulatory role of miR-9/9*, -338-3p and -335/335* in the expression of their puta-
tive targets. First, we explored whether transfection of each cybrid model with a miRNA antagonist (anti-miR) 
led to the recovery of the targeted genes. Previous results indicated that transfection of the MELAS cybrid line 
with anti-miR-9 led to a noticeable increase in the mRNA and protein levels of GTPBP3 and TRMU4. Here, we 
observed that transfection of MERRF cells with anti-miR-9 also caused a clear accumulation of the GTPBP3 and 
TRMU mRNAs (Fig. 5A). No changes in the expression of MTO1 were found in the MERRF transfected cells 
(Fig. 5A), as expected given that MTO1 is a direct target of miR-9* but not of miR-94. In addition, we transfected 
MELAS cells with anti-miR-338-3p and no changes were observed in the mRNA expression of the putative miR-
338-3p targets, GTPBP3 and TRMU (Fig. 5B), which could be due to the low expression level of miR-338-3p in 
the cybrids. Finally, we found a recovery of the GTPBP3 expression after transfection of m.Trp and m.Val with 
anti-miR-335 (Fig. 5C and D), which is in agreement with the prediction that this gene, but not MTO1 and 
TRMU, is a target of miR-335 (Table S1).
Second, we explored the capability of miRNAs to bind to their predicted targets. As we previously demon-
strated that GTPBP3 and TRMU are directly targeted by miR-9, whereas MTO1 is targeted by miR-9*4, we 
focused here on testing the binding of miR-335/335* and miR-338-3p to their targets by means of luciferase 
reporter assays. To this end, we cloned the 3′UTR of the respective mRNAs in direct (+) or reverse (−) direction 
downstream of the luciferase reporter gene. Then, we co-transfected these plasmids into Hela cells together with 
the respective microRNA mimic (Pre-miR) or its negative control (NC-Pre-miR). The co-transfection of the 
GTPBP3 and MTO1 reporters together with miR-335 or miR-335* mimic, respectively, caused a decrease of over 
30% in the luciferase activity as compared with the negative control-transfected cells (Fig. 5E and F). Moreover, 
the co-transfection of the GTPBP3 and TRMU reporters together with miR-338-3p mimic resulted in a decrease 
of about 50% in the luciferase activity (Fig. 5G and H). These effects were lost when assays were performed with 
reporters carrying the 3′UTR of each gene in the reverse direction (Fig. 5E–H). Altogether these data indicate that 
the selected miRNAs indeed bind to their predicted targets.
Briefly, our results demonstrate that miR-9/9* is a direct regulator of the GTPBP3, MTO1 and TRMU expres-
sion in MERRF cells, whereas miR-335/335* controls the expression of GTPBP3 and MTO1 in m.Trp and m.Val 
cells. Despite miR-338-3p targets GTPBP3 and TRMU, this miRNA does not appear to play an important role 
in the regulation of these genes in the MELAS and MERRF cybrids, likely because of its low expression level in 
these cells.
miR-9 and miR-335 contribute to worsen the phenotype of specific cybrid models. 
Downregulation of GTPBP3, or MTO1 or TRMU by siRNAs has been previously shown to affect mitochondrial 
protein synthesis, cellular ATP content, mitochondrial membrane potential, and oxygen consumption37–39. To 
evaluate the functional effect of down-regulation of the U34 modification enzymes mediated by miRNAs, we 
analyzed the effects produced by either the transfection of cybrid cells with anti-miRs or the transfection of 
wild-type cells with pre-miRs. As shown in Fig. 6, the ATP levels of MELAS and MERRF cells or m.Trp and m.Val 
cells increased significantly after transfection with anti-miR-9 (Fig. 6A and B) or anti-miR-335 (Fig. 6C and D), 
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respectively. No increase of the ATP levels was observed after transfection of MELAS cells with anti-miR-338-3p 
(Fig. 6E). Altogether these data indicate that up-regulation of miR-9/9* in MELAS and MERRF cells, and of 
Figure 3. The 2-thiouridylation status of mt-tRNALys depends on the TRMU expression level. (A) APM-
Northern analysis of the 2-thiolation status of mt-tRNALys obtained from mutant and WT cybrid cells. The same 
amount of total RNA (7.5 µg) was run in a denaturing polyacrylamide-urea gel in the presence (+) or absence 
(−) of APM. The thiolated tRNAs were detected as retarded bands in the presence of APM. The APM (−) 
membrane was also probed with 5S rRNA as a loading control. (B) Relative steady-state levels of mt-tRNALys. 
The signal corresponding to the amount of mt-tRNALys in the APM (−) membrane was normalized to the signal 
corresponding to the amount of 5S rRNA and represented as fold change relative to WT. Full-length blots and 
lower-exposure blots for the APM (+) membranes are included in supplementary information. (C) Percentage 
of thiolated and nonthiolated mt-tRNALys species compared with the whole amount of this mt-tRNA. The 
quantification of each fraction (thiolated or nonthiolated) is expressed as a percentage of its signal from the 
total signal (thiolated + non-thiolated signals). All data represent the mean ± SD of at least three different 
experiments. Differences from WT values were found to be statistically significant at *p < 0.05.
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miR-335/335* in m.Val and m.Trp cells contributes to their energetic deficit, and that miRNA-338-3p plays an 
irrelevant role in the phenotype of MELAS and MERRF cybrids.
The increase in the ATP levels observed in MELAS cells after transfection with anti-miR-9 (Fig. 6A) corre-
lates with an increase of both the TRMU expression4 and the 2-thiolation levels of mt-tRNALys (Fig. 6F and G). 
Moreover, the decrease in the ATP levels observed in wild-type cells after transfection with pre-miR-9 (Fig. S2A) 
correlates with a decrease of the TRMU expression and 2-thiolation levels of mt-tRNALys (Fig. S2B–D). 
Interestingly, transfection of the wild-type cells with pre-miR-9 or TRMU-siRNAs produces similar effects: a 
decrease in the TRMU expression, a decrease in the thiolation levels of mt-tRNALys, and a decrease in the cellular 
ATP levels (Figs S2 and S3; see also ref. 4). Altogether these data suggest that the functional effect of miR-9 occurs, 
at least partially, through the mt-tRNA modification function of TRMU.
Critical thresholds of ROS and Ca2+ determine the expression levels of miR-9 and miR-335*. It 
is striking that the expression of GTPBP3 and MTO1 is controlled by miR-9/9* in MELAS and MERRF cybrids, 
and by miR-335/335* in m.Trp and m.Val cells. We asked whether the different expression pattern of miRNAs 
among the cybrid lines could depend on threshold levels of retrograde signals like ROS and Ca2+. To address 
this question, we first analysed the effects of the antioxidant N-acetyl-cysteine (NAC) and the intracellular Ca2+ 
chelator 1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA) on 
the expression of miR-9 and miR-335 in the cybrid lines. We found that the reduction of ROS and Ca2+ levels by 
NAC and BAPTA treatments (Fig. S4A and B, respectively) caused a decrease in the induced levels of miR-9 in 
MELAS and MERRF cybrids (Fig. 7A and B) and of miR-335* in m.Trp and m.Val cells (Fig. 7C). In addition, 
we observed that, despite the decreased expression of miR-9 in ND6 cells (Fig. 7D) and the uninduced or very 
low levels of miR-335* in MELAS, MERRF and ND6 (Fig. 7A,B and D), the expression of both miRNAs could 
be further reduced after treatment of the cells with the antioxidant (NAC) or Ca2+ chelating (BAPTA) agent. A 
reduction in the miR-9 and miR-335 levels was also observed in WT cybrids treated with these agents (Fig. S6). 
These data support the idea that certain minimum threshold levels of ROS and Ca2+ are required for wild-type 
expression of miR-9 and miR-335*.
Next, considering that the ROS and Ca2+ levels reached in MELAS and MERRF cybrids were higher than in 
m.Trp and m.Val cells (Fig. 1F and G), we evaluated the effect of increasing the levels of ROS or Ca2+ in the m.Trp 
and m.Val cybrids by treatment with H2O240, 41 or Thapsigargin42. Notably, the first one increased the levels of 
both ROS and Ca2+ (Figs S5A and S5B), whereas Thapsigargin only had an effect on the Ca2+ levels (Figs S5C and 
S5D). Interestingly, we found that miR-9 was induced in m.Trp and m.Val cells after both treatments, although 
the induction was higher in the H2O2-treated cells (Fig. 8A, left), and that the effect of Thapsigargin and H2O2 
was quenched by pre-treatment of cells with BAPTA and NAC, respectively (Fig. S7), which indicates that the 
induction of miR-9 is mediated by the levels of Ca2+ and ROS. In contrast, the expression of miR-335* in the 
m.Trp and m.Val cells was not further increased after treatment with Thapsigargin or H2O2 (Fig. 8A, right). These 
data indicate that the increase of ROS and/or Ca2+ levels in m.Trp and m.Val cells promotes the induction of 
miR-9, while leaving roughly unaffected the high expression of miR-335*. It should be mentioned that treatment 
of MELAS cells with Thapsigargin or H2O2 did not affect significantly the expression of miR-9 and miR-335* 
Figure 4. Mutation-dependent expression of miRNAs that are predicted to target the U34 modification 
enzymes. (A–D) qRT-PCR analysis of the miR-9/9* (A), miR-338-3p (B), and miR-335/335* (C) expression 
in mutant and WT cybrid cells. Results from this analysis are also shown as a heatmap (D). The color and the 
corresponding value in log2 scale are depicted on the left. All data are the mean ± SEM of at least three different 
experiments. Differences from WT values were found to be statistically significant at *p < 0.05, **p < 0.01 and 
***p < 0.001. AU: arbitrary units.
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(Fig. S8), suggesting that the endogenous levels of ROS and Ca2+ in MELAS cells include the maximum threshold 
required for induction of miR-9.
The fact that miR-335* remains highly induced in Thapsigargin- or H2O2-treated m.Trp and m.Val cells (i.e., 
in the presence of increased levels of ROS and Ca2+) (Fig. 8A), while its expression is not induced in the MELAS 
and MERRF cells (Fig. 4C and D) suggests that miR-335* requires an additional, still unknown, signal to be 
induced, which is not present in MELAS and MERRF cells.
We have previously demonstrated that oxidative stress mediates the induction of miR-9/9* via an 
NFkB-dependent signaling pathway4. NFkB activation is initiated by the signal-induced degradation of IkB 
repressor proteins, which triggers the translocation of NFkB from the cytoplasm to the nucleus, thus activating 
the transcription of the target genes, like miR-9. We found that the IKBα expression is compromised not only in 
Figure 5. miR-9/9*, miR-338-3p, and miR-335/335* are regulators of the U34 modification enzymes.  
(A–D) qRT-PCR (left) and Western blot (right) analysis of GTPBP3, MTO1 and TRMU expression in anti-miR-
9-transfected MERRF cells (A), anti-miR-338-3p-transfected MELAS cells (B), anti-miR-335-transfected m.Trp 
cells (C) and anti-miR-335-transfected m.Val cells (D), and in the respective negative control (NC)-transfected 
cells (A–D). Full-length western blots are included in supplementary information. (E) Effects of miR-335 
transfection on the activity of luciferase reporter constructs containing the GTPBP3-3′-UTR in the direct (+) 
or reverse (−) direction. (F) Effects of miR-335* transfection on the activity of luciferase reporter constructs 
containing the MTO1-3′-UTR in the direct (+) or reverse (−) direction. (G and H) Effects of miR-338-3p 
transfection on the activity of luciferase reporter constructs containing the GTPBP3-3′-UTR (G) and TRMU-
3′-UTR (H) in the direct (+) or reverse (−) direction. All data are the mean ± SEM of at least three different 
experiments. Differences from NC values were found to be statistically significant at *p < 0.05, **p < 0.01 and 
***p < 0.001. RLU: Relative light units.
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MELAS but also in MERRF cells, whereas it remains unaffected in m.Trp, m.Val, and m.ND6 (Fig. S9). These data 
suggest that induction of miR-335/335*, unlike that of miR-9/9*, is independent of NFkB. As expected, the treat-
ment of m.Trp, and m.Val cybrids with H2O2 or Thapsigargin led to a decrease in the IKBα expression (Fig. S10), 
which correlates well with the induction of miR-9 observed in the treated cells (Fig. 8A).
Figure 6. The induction of miR-9/9*, miR-338-3p and miR-335/335* worsens the energetic state of the cybrid 
lines. (A–E) Cellular ATP determination in anti-miR-9 transfected MELAS cells (A), anti-miR-9-transfected 
MERRF cells (B), anti-miR-335-transfected m.Trp cells (C), anti-miR-335-transfected m.Val cells (D), anti-miR-
338-3p-transfected MELAS cells (E) and in the respective negative control (NC)-anti-miR transfected cells (A–
E). (F) APM-Northern analysis of the 2-thiolation status of mt-tRNALys obtained from MELAS cells transfected 
with either anti-miR-9 or NC-anti-miR. The thiolated tRNAs were detected as retarded bands in the presence of 
APM. The membrane was also probed with 5S rRNA as a loading control. Full-length blots and a lower-exposure 
blot of mt-tRNALys are included in supplementary information. (G) Percentage of thiolated and nonthiolated 
mt-tRNALys species compared with the whole amount of this mt-tRNA. The quantification of each fraction 
(thiolated or nonthiolated) is expressed as a percentage of its signal from the total signal (thiolated + non-
thiolated signals). All data are the mean ± SEM of at least three different experiments. Differences from negative 
control (NC) values were found to be statistically significant at *p < 0.05 and **p < 0.01.
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In order to analyze the biological consequences of the induction of miR-9 in the H2O2- and 
Thapsigargin-treated m.Trp and m.Val cells, we assessed the expression of TRMU since this gene is a target 
of miR-9, but not of miR-335/335* (Table S1). The miR-9 induction in H2O2- or Thapsigargin-treated m.Trp 
and m.Val cells produced a concomitant decrease of TRMU expression, being more acute in H2O2-treated cells 
(Fig. 8B–D). These data are in line with the idea that threshold levels of ROS and Ca2+ induce miR-9/9* and mod-
ify the expression pattern of nucleus-encoded proteins, including the mt-tRNA modification enzymes.
Discussion
Modifications at wobble uridines in tRNAs have been shown to regulate global protein expression by promot-
ing selective translation of codon-biased mRNAs8, 22, 43, influencing nascent chain folding44, and contributing 
to signaling functions of tRNAs45–47. There is emerging evidence for reprogramming of U34 modifications in 
response to stress4, 22, 48. However, the regulatory mechanisms controlling the expression of tRNA modification 
enzymes and their role in the modification reprogramming are poorly known. In this study, we demonstrate that 
the expression of the mt-tRNA modifying enzymes GTPBP3, MTO1 and TRMU varies in response to different 
pathological mtDNA mutations, thus altering the modification status of mt-tRNAs. Importantly, we demonstrate 
that the expression of these enzymes is regulated by different miRNAs, whose activation depends on retrograde 
stress signals like ROS and Ca2+.
We used five different cybrid models of mtDNA mutations: four of them carry mutations in mt-tRNA genes, 
while the fifth contains a mutation affecting the complex I subunit ND6. In all mutant cybrid lines, including 
m.ND6, we observed a differential induction of mitoproteases involved in protein quality control and mitori-
bosome assembly, and an altered expression of GTPBP3, MTO1 and TRMU. Our data suggest that the up- or 
down-regulation of the U34 modification enzymes is part of a cellular response to cope with a stoichiometric 
imbalance between mtDNA- and nDNA-encoded OXPHOS subunits, which causes proteostasis stress.
Recent data indicate that the U34 of mt-tRNALys, mt-tRNAGlu and mt-tRNAGln from mouse hepatocytes is 
not fully modified36. In agreement with this, our data show that mt-tRNALys from wild-type cybrids is partially 
thiolated. Therefore, there is a chance that the non-modified/modified ratio of the mt-tRNA substrates for TRMU, 
GTPBP3 and MTO1 can be increased or decreased in response to stress, and that regulation of this ratio depends 
on the expression levels of the U34 modification enzymes. Both an increase and a decrease of mitochondrial 
translation may be involved in stress responses. Notably, it has been shown that the modifications introduced by 
the E. coli orthologs of TRMU (at position 2 of U34), and GTPBP3 and MTO1 (at position 5 of U34) modulate 
differently the relative efficiency of anticodons in reading cognate codons49. Moreover, the 2-thio group, but not 
the group introduced by the GTPBP3 and MTO1 orthologs, is important for aminoacylation50. These roles of the 
bacterial U34 modifications could be conserved by their counterparts in mt-tRNAs. Furthermore, we cannot rule 
Figure 7. Elevated levels of ROS and intracellular Ca2+ stimulate the expression of miR-9/9* and miR-335/335* 
in mutant cybrid cells. (A–D) qRT-PCR analysis of miR-9 and miR-335* expression in MELAS (A), MERRF 
(B), m.Trp, m.Val (C) and m.ND6 (D) cybrid cells treated with either 1 mM NAC (antioxidant) for 48 h or 
10 μM BAPTA (Ca2+ chelator) for 2 h. All data are the mean ± SEM of at least three different experiments. 
Differences from WT values were found to be statistically significant at *p < 0.05 and **p < 0.01.
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out the possibility that U34 modifications may increase stability of mt-tRNAs. The different roles played by these 
modifications could explain the differential expression of the U34 modification enzymes in some cybrids. Thus, 
it is possible that the two types of U34 modifications (TRMU- and GTPBP3/MTO1-dependent) regulate mito-
chondrial translation according to the particular perturbation of proteostasis caused by each mtDNA mutation.
There are evidences, from a mouse model lacking a protein directly involved in mitochondrial translation, that 
the activation of adaptive responses to the impairment of mitochondrial proteostasis precedes respiratory chain 
deficiency during the development of mitochondrial diseases51. Our results clearly show that the five mutant 
cybrid lines differ in the expression of the mitoproteases LONP1, AFG3L2 and CLPP, which suggests that each 
Figure 8. Treatment of m.Trp and m.Val cybrids with Thapsigargin or H2O2 triggers the expression of miR-9 
and reduces the TRMU levels. (A) qRT-PCR analysis of miR-9 and miR-335 expression in m.Trp, m.Val and 
WT cybrid cells treated with either 400 nM Thapsigargin (THAP) for 24 h or 5 mM H2O2 for 6 h. (B) qRT-
PCR analysis of TRMU mRNA expression in m.Trp, m.Val and WT cybrid cells treated with either 400 nM 
Thapsigargin (THAP) for 24 h or 5 mM H2O2 for 6 h. (C) Representative western blot of the expression of 
TRMU in m.Trp, m.Val and WT cybrid cells treated with either 400 nM Thapsigargin (THAP) for 24 h (left) 
or 5 mM H2O2 for 6 h (right). The membrane was also probed with porin as a loading control. Full-length 
western blots are included in supplementary information. (D) Densitometric analysis of TRMU normalized 
to porin and represented as fold change relative to WT. All data are the mean ± SEM of at least three different 
experiments. Differences from WT values were found to be statistically significant at *p < 0.05, **p < 0.01 and 
***p < 0.001.
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mutation triggers an adaptive response to compensate the perturbation in the stoichiometric balance between 
components of OXPHOS complexes. Apparently, these adaptive responses are not able to restore the mitonu-
clear balance in the MELAS, MERRF, m.Trp and m.Val cybrids, since all of them exhibit a strong decrease in the 
steady-state levels of at least complex IV, and increased levels of ROS and Ca2+. These retrograde signals unleash 
a second wave of nuclear responses, including up- or down-regulation of miRNAs involved in the control of the 
U34 modification enzymes, thus altering the ratio of modified/unmodified mt-tRNA molecules. Variations in the 
modification state of the U34 in mt-tRNAs may affect both the global mitochondrial translation as well as putative 
non-conventional functions of mt-tRNAs (for instance, cell signaling). These successive waves of stress responses 
fail, however, to provide full protection from the OXPHOS dysfunction; rather, they appear to aggravate some 
phenotypic traits of the disease cell models since the transfection of these cybrids with appropriate anti-miRs 
improves the energetic state of the cells.
Interestingly, GTPBP3 and MTO1 are down-regulated in all cybrid lines carrying mutations in mt-tRNA 
genes (MELAS, MERRF, m.Trp, and m.Val cells), although down-regulation occurs via different miRNAs 
(miR9/9* in MERRF and MELAS; miR335/335* in m.Trp and m.Val). Our data indicate that both miR-9/9* 
and miR-335/335* require relatively high levels of ROS and Ca2+ to be induced, as the treatment of the MELAS, 
MERRF, m.Trp and m.Val with the antioxidant agent NAC or the Ca2+ chelator BAPTA reduced the expression of 
the up-regulated miRNAs. Our data also show that the NFkB-dependent induction of miR-9/9* requires thresh-
old levels of ROS and/or Ca2+, given that the increase of these signals by treatment with H2O2 or Thapsigargin 
led to the induction of miR-9 in m.Trp and m.Val cells without severely affecting the high expression levels of 
miR-335. However, the induction of miR335/335* requires an additional factor(s) that remains to be identified, 
as the elevated levels of ROS and Ca2+ inherent to the MERRF and MELAS cybrids did not lead to the induction 
of this miRNA in both cybrid lines. The unaltered expression of the IkBα repressor found in the m.Trp and m. 
Val cybrids suggests that NFkB is not responsible for the induction of miR-335/335*. Putative regulators of this 
miRNA are the transcription factor CREB52 and the cAMP/PKA pathway53. Further studies are needed to explore 
these possibilities and clarify the miR-335/335* induction pathway.
TRMU is down-regulated in MELAS and MERRF cybrids, but up-regulated in m.Trp and m.Val cells, at both 
mRNA and protein levels. TRMU is a target of miR-9, but the levels of this miRNA in m.Trp and m.Val cells are 
similar to those found in the WT cybrid. Thus, the TRMU up-regulation in m.Trp and m.Val does not appear to 
depend on the miR-9 levels. It is worthy to note that TRMU is a target of other miRNAs (Table S1), which have 
not been included in this study due to the selection criteria. Therefore, it is possible that some of these miRNAs 
are down-regulated by the retrograde signaling pathway(s) activated in the mt.Trp and mt.Val cells, which would 
lead to the TRMU mRNA overexpression. Alternatively, the TRMU induction in the mt.Trp and mt.Val cells 
could be regulated at transcriptional levels. The biological meaning behind the induction of TRMU in a context 
(m.Val and m.Trp cells) where GTPBP3 and MTO1 are down-regulated remains unclear, but it could be related to 
new, still unknown functions of these enzymes and/or, as aforementioned, to the specific role of the modifications 
(s2 and τm5) introduced by the enzymes10, 54, 55.
The m.ND6 cells exhibited a behavior different from the rest of the mutant cybrids. No significant changes in 
the steady-state levels of the OXPHOS complexes were observed in the m.ND6 cells, although proteases LONP1, 
AFG3L2 and CLPP were found to be overexpressed. Moreover, there was a clear tendency to the accumulation 
of proteins TRMU, GTPBP3 and MTO1 in these cells, despite the mRNA levels were similar to those found in 
the WT cybrids. These data suggest that either the translation or the stability of the U34 modification enzymes 
is improved in the m.ND6 cells. Interestingly, the expression of miRNA-9/9*, miRNA-338-3p and, particularly, 
miRNA-335/335* was severely down-regulated in these cells, which could be part of a program to guarantee a 
high expression level of GTPBP3, MTO1 and TRMU in the genetic context of the m.ND6 cybrid line.
In brief, it appears that cells may function normally with a certain level of hypomodified mt-tRNAs, and that 
variations in this level represent a mechanism to regulate expression of mtDNA-encoded proteins as an adaptive 
response to the impairment of mitochondrial proteostasis. This work demonstrates the crucial role of miRNAs 
in the regulation of TRMU, GTPBP3 and MTO1, and, accordingly, in the modification status of the mt-tRNAs.
Methods
Materials. N-acetylcysteine, Thapsigargin and Hydrogen peroxide (H2O2) were purchased from Sigma. 
1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl) ester (BAPTA-AM) was 
purchased from Tocris. The APM ([p-(N-acrylamino)-phenyl]mercuric chloride) was synthesized and kindly 
provided by Prof. Stephane Vincent56. Oligonucleotides (Table S2) were purchased from Sigma and Qiagen.
Cell culture. Transmitochondrial cytoplasmic hybrids (cybrids) were previously generated by fusion of 
platelets, derived from five patients carrying m.3243 A > G, m.8344 A > G, m.5514 A > G, m.1643A > G and 
m.14487 T > C mutations, respectively, with human osteosarcoma 143B cells lacking mtDNA (ρ0 cells). Briefly, 
platelet cells were isolated from a blood sample and fused to a large excess of mtDNA-less human osteosar-
coma 143B (TK−) cells by using polyethylene glycol, as described57. Different cybrid clones were obtained by 
culturing the fusion mixture in selective Dulbecco’s modified Eagle’s medium (DMEM) (Biological Industries, 
Kibbutz Beit Haemek, Israel) containing glucose (4.5 g/l), pyruvate (0.11 g/l), 10% dialyzed fetal bovine serum 
(FBS) (Invitrogen, Carlsbad, CA, USA) and 100 μg/ml BrdU (5-bromo-2-deoxyuridine; without uridine) to pre-
vent growth of TK + donor cells. Different clones were selected, DNA extracted from each clone and analyzed by 
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to find cells containing 100% 
mutant mtDNA or the wild type counterpart (WT cybrids). The presence or absence of the mutation in the cells 
was periodically confirmed using a PCR-RFLP assay24, 25, 58. All cybrids were cultured in high glucose Dulbecco’s 
modified Eagle medium (Gibco) containing 10% fetal bovine serum, 1 mM sodium pyruvate, 100 U/ml penicillin, 
100 μg/ml streptomycin, 2 mM glutamine and 1 mM non-essential amino acids. Human HeLa cells were grown in 
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full medium: Minimum Essential Medium (MEM) (Sigma) supplemented with 10% heat-inactivated fetal bovine 
serum, 100 U/ml penicillin and 100 μg/ml streptomycin.
Anti-miR and pre-miR transfection. Cells were seeded at 250,000 cells/well in 6 well-plate or at 
1,500,000 cells/100mm dish. After 24 h, cells were transfected with one of the RNA oligonucleotides (Anti-miR-9, 
anti-miR-335, anti-miR-338-3p, Negative Control (NC)-anti-miR, pre-miR-338-3p, pre-miR-335, pre-miR-335* 
or Negative Control (NC)-pre-miR; Applied Biosystems) at the 50 nM final concentration, using Lipofectamine 
2000 reagent (Invitrogen) and Opti-MEM medium according to the manufacturer’s instructions. After 6 h of 
transfection, the medium was changed to fresh growth medium. Cells were collected after 48 h of transfection.
APM-Northern blotting analysis. The procedure was performed as previously described to assess the thi-
olation status of mitochondrial tRNAs4. Total RNA (7.5 μg) was run on a 15% polyacrylamide gel containing 7 M 
urea and 10 μg/ml APM and then transferred to positively charged nylon membranes (Roche). Pre-hybridization 
and hybridization steps were performed with Dig Easy Hyb (Roche) according to the manufacturer’s instructions. 
mt-tRNALys was detected with a specific DIG-labeled synthetic oligodeoxynucleotide (Table S2). Quantification of 
the non-radioactive signals was performed with ImageQuant TL v8.1 (GE Healthcare Life Sciences). The fraction 
of thiolated and non-thiolated tRNAs was calculated as described15. Briefly, the quantification of each fraction was 
expressed as a percentage of the thiolated or the non-thiolated signal from the thiolated + non-thiolated signals 
(as detected on the (−) APM gel).
Luciferase reporter assays. The luciferase reporter plasmids, containing the 3′UTRs of GTPBP3, MTO1 
and TRMU genes, were obtained as described4. HeLa cells were seeded at 50,000 cells/well, and the following 
day, 500 ng of a Luciferase reporter plasmid and, as an internal control, 25 ng of Renilla Luciferase control vector 
(Promega) were co-transfected together with one of the RNA oligonucleotides at the 50 nM final concentration, 
using Lipofectamine 2000 reagent (Invitrogen) and Opti-MEM medium according to the manufacturer’s instruc-
tions. After 48 h, cells were lysed and Firely and Renilla luciferase activities from the cell extracts were measured 
with the Dual-luciferase Reporter Assay System (Promega) following the manufacturer’s procedure.
RNA isolation and qRT-PCR. Total RNA was isolated using TRIzol reagent (Invitrogen). To quantify 
mRNA levels, one-step qRT-PCRs were performed in an Applied Biosystems Step-One Real-Time PCR System. 
50-300 ng of total RNA were reverse-transcribed and amplified by qPCR in 20 μl of total volume reaction con-
taining specific primers (Sigma), Power SYBR Green PCR Master Mix, MultiScribe Reverse Transcriptase, and 
RNase Inhibitor (all from Applied Biosystems), according to the manufacturer’s instructions. The efficiency values 
obtained for qPCR amplifications were very near to 2. Relative quantitation of mRNA levels was calculated using 
the comparative Ct method. ACTB gene was used as endogenous control. A list of the primers used in this work 
is provided in Table S2. The absolute abundances of GTPBP3, MTO1 and TRMU mRNAs were estimated to be 
in a range of 1 to 15 copies/cell in mutant cybrid cells by using equivalent calculations as described4. For miRNA 
quantification, 10 ng of total RNA were reverse-transcribed in 15 μl total reaction using the MultiScribe reverse 
transcriptase and specific stem-loop RT primers (Applied Biosystems). Then, 1.33 μL of cDNA was subjected to a 
TaqMan miRNA assay (Applied Biosystems), in a total reaction volume of 20 μL using specific primers and probes 
for human miR-9, miR-9*, miR-338-3p, miR-335, miR-335* and U6 snRNA, according to the manufacturer’s 
protocol. Expression values were calculated using the comparative CT method. U6 snRNA was used as an endog-
enous control. The absolute abundances of either miR-9, miR-9*, and miR-338-3p in MELAS and MERRF cybrid 
cells or miR-335 and miR-335* in m.Trp and m.Val cybrid cells were also estimated as described4. We estimated 
the abundance of miR-9 and miR-9* to be at about 2200 and 250 copies/cell, respectively. miR-338-3p was found 
at approximately 15 and 35 copies/cell in MELAS and MERRF cybrid cells, respectively, whereas miR-335 and 
miR-335* were at 280 and 260 copies/cell in m.Trp cybrid cells and at 810 and 700 copies/cells in m.Val cybrid 
cells. Only the amounts of miR-9, miR-9*, miR-335 and miR-335* in the cell exceed the necessary threshold level 
of miRNA expression (100 copies/cell) proposed for significant target suppression59.
Measurement of mitochondrial DNA. mtDNA quantification was performed by qPCR as previously 
described60.
Measurement of intracellular ATP. The amount of ATP was measured with the ATP Bioluminescence Kit 
Assay Kit HSII (Roche), following the manufacturer’s instructions. Measurements were performed after the treat-
ment or 48 h after transfection. Briefly, cells were detached with trypsin-EDTA, resuspended with fresh medium, 
centrifuged at 100 g and resuspended again with kit dilution buffer at 106 cells/mL. Then, the same volume of kit 
cell lysis reagent was added to the cell suspension and the mixture incubated for 5 min at room temperature. After 
transferring the appropriate volume of sample into a microwell plate well, the kit luciferase reagent was added. 
Luminescence was determined using the Spectra Max M5 (Molecular Devices).
Flow cytometry studies. After the indicated treatments, cells were detached at 37 °C with trypsin-EDTA 
and resuspended in fresh growth media. For ROS analysis, cells were incubated with 5 μM MitoSOX Red for 
30 min at 37 °C, washed twice with phosphate buffered saline (PBS), and the red fluorescence emitted by the dye 
(540–625 nm band-pass filter) was measured39. For intracellular calcium determination, cells were incubated 
with 5 μM Fluo-3-AM for 30 min at 37 °C, washed twice with phosphate buffered saline (PBS), and the emitted 
fluorescence (488 ± 20-nm band-pass filter) was recorded61. For all the measurements, 10,000 cells were analysed 
and collected using a Cytomics FC 500 flow cytometer (Beckman Coulter).
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Blue-Native PAGE. BN-PAGE was performed similarly as described62. In brief, mitoplasts were prepared 
by treatment with 1.2 mg digitonin per mg of protein, and were then solubilized with 1% lauryl maltoside, which 
is a mild non-ionic detergent that allows for separation of individual complexes (complexes I-V) rather than 
retaining the supercomplexes. Samples containing 10–20 µg of protein were separated on a 3–12% Bis-Tris Novex 
NativePAGE gel (Life Technologies). The relative level of the assembled respiratory complexes I-IV was assessed 
by Western blot with commercially antibodies: mouse monoclonal anti-NDUFB8 antibody (459210, Invitrogen), 
mouse monoclonal anti-SDHA antibody (ab14715, Abcam), mouse monoclonal anti-Complex III subunit Core 1 
antibody (459140, Invitrogen) and rabbit polyclonal anti-COX IV antibody (459600, Invitrogen). Complex V was 
detected with a rabbit polyclonal antibody63.
Western blot. Cell extracts were prepared in RIPA buffer (150 mM NaCl, 1% Nonidet P40, 0.5% sodium 
deoxycholate, 0.1% SDS and 50 mM Tris-HCl pH 8.0), containing 0.1 mM leupeptin and 1 mM phenylmeth-
anesulphonyl fluoride. When phosphoproteins were assessed, cell extracts were prepared in lysis buffer (10 mM 
NaCl, 1% Nonidet P40, 15% Glycerol, and 50 mM Tris-HCl pH 7.4), containing 1 mM phenylmethanesulpho-
nyl fluoride, 0.1 mM leupeptin, 2 mM sodium orthovanadate, 100 mM sodium fluoride and 20 mM tetrasodium 
pyrophosphate. Proteins (100 μg) from the various lysates were separated by SDS/PAGE (10% acrylamide) and 
transferred to PVDF membranes (GE Healthcare, Amersham Biosciences). For immunodetection, anti-GTPBP3 
antibody was purified from GTPBP3-His-inoculated rabbit serum39. The others were commercial: rabbit pol-
yclonal anti-MTO1 antibody (15650-1-AP, Protein tech), rabbit polyclonal anti-TRMU (sc-86923, Santa Cruz 
Biotechnology), rabbit polyclonal anti-porin antibody (ab15895, Abcam), rabbit polyclonal anti-LONP1 (NBP1-
81734, Novus Biologicals), mouse polyclonal anti-AFG3L2 (ab68023, Abcam), rabbit monoclonal anti-CLPP 
(ab124822, Abcam), rabbit polyclonal anti-IKBα (sc-847, Santa Cruz Biotechnology). The anti-rabbit (A6154) 
and anti-mouse (A4416) IgG-horseradish peroxidase-conjugated secondary antibodies were obtained from 
Sigma. Protein bands were quantified by densitometric analysis with an Image Quant ECL (GE Healthcare).
Statistical analysis. Statistical analysis was performed using Student’s t test. The statistically signif-
icant differences between the means were indicated by asterisks (*p < 0.05, **p < 0.01 or ***p < 0.001), and 
non-significant differences by n.s.
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